Related Articles
Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line
miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway
Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway
Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor‑tyrosine kinase inhibitor via the PI3K/AKT pathway in non‑small cell lung cancer cells<em> in vitro</em>